Which one is better, Cemiplimab or K-drug?

The k drug in domestic clinical practice refers to pembrolizumab (Pembrolizumab), Cemiplimab (Cemiplimab) and pembrolizumab are PD-1 antibodies that are immunotherapy drugs, The effectiveness and safety of both have been confirmed in clinical trials, but they may produce different responses in different patients. Cimepilimab is suitable for cutaneous squamous cell carcinoma (SCC), non-small cell lung cancer (NSCLC), and cervical cancer, while pembrolizumab is suitable for a variety of malignant tumors, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma. It is impossible to determine which drug is better because each patient's situation is unique.